Author: Francesco Collacchi

Recombinant proteins stand as one of the groundbreaking biotechnological innovations of recent decades. These remarkable biomolecules, engineered by inserting the gene for a specific protein into a host organism, transform these cells into “living factories” capable of synthesizing the desired protein.

This cutting- edge technology unlocks unprecedented opportunities including:

  • Producing human proteins in non-human systems
  • Yielding large quantities of rare proteins
  • Crafting proteins with enhanced or entirely novel functionalities.

In this dynamic landscape of scientific advancement, Diatheva emerges as a leading company in advanced biotechnological solutions, placing recombinant proteins at the core of its innovative mission.

Diatheva’s Expertise in Recombinant ProteinsDevelopment and Production of Recombinant Antigens for Diagnostics: Diatheva harnesses the power of recombinant protein technology to design and produce highly specific and sensitive antigens, crucial components in modern diagnostic assays.

These innovative tests find applications across various fields, from the early detection of cancers and infectious diseases (such as HIV and Hepatitis C) to the management of public health emergencies like the recent COVID-19 pandemic, where rapid antigen tests based on recombinant proteins proved essential.

Recombinant Monoclonal Antibodies: Precision & Consistency

Diatheva’s expertise extends to the production of recombinant monoclonal antibodies, indispensable tools for in vitro and in vivo diagnostics, as well as for the development of targeted therapies.

Unlike traditional monoclonal antibodies, recombinant technology ensures: the production of antibodies with high specificity and batch-to-batch consistency.

Custom Recombinant Protein Production for Therapeutic and Non-Therapeutic Applications

Diatheva offers tailored recombinant protein production services to support the development of innovative therapeutic strategies for various diseases. Furthermore, the company produces recombinant proteins for non-therapeutic applications, catering to the needs of the veterinary and environmental monitoring sectors.

Comprehensive Support for Research and Development

With its profound understanding of recombinant proteins, Diatheva positions itself as an ideal partner for companies and research institutions requiring specialized expertise in the design, production, and characterization of these biomolecules for their R&D endeavors.

While acknowledging the existing challenges in recombinant protein production and application, such as high production costs and the necessity of ensuring correct three-dimensional folding of complex proteins, Diatheva is continuously committed to adopting optimized production and purification processes and exploring advanced expression systems to overcome these limitations.

The Future: Protein Engineering & AI

With a keen eye on the horizon, Diatheva is excited by the transformative potential of protein engineering and artificial intelligence.

We firmly believe that these groundbreaking tools will significantly expedite the discovery of revolutionary recombinant proteins, enabling us to contribute even more effectively to global health and environmental well-being.

 

Francesco Collacchi is Quality Control Analyst at Diatheva. With a background in biotechnologies, biochemical and pharmacological methodologies from the University of Urbino, he ensures the reliability of products through advanced analytical techniques, supporting Diatheva’s standards of quality and innovation.